Dana Investment Advisors, Inc. Travere Therapeutics, Inc. Transaction History

Dana Investment Advisors, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$15.3 - $22.61 $97,767 - $144,477	6,390 Added 26.18%	30,801 $473,000
Q1 2023 May 15, 2023	SELL	$17.82 - $22.89 $16,911 - $21,722	-949 Reduced 3.74%	24,411 $549,000
Q4 2022 Feb 13, 2023	BUY	$18.47 - $26.14 $108,049 - $152,919	5,850 Added 29.98%	25,360 $533,000
Q3 2022 Nov 15, 2022	SELL	$22.91 - $28.63 $20,069 - $25,079	-876 Reduced 4.3%	19,510 $481,000
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $10,239 - $14,674	-489 Reduced 2.34%	20,386 $494,000
Q1 2022 May 12, 2022	SELL	$23.61 - $30.6 $4,084 - $5,293	-173 Reduced 0.82%	20,875 $538,000
Q4 2021 Feb 09, 2022	SELL	$24.34 - $31.17 $57,539 - $73,685	-2,364 Reduced 10.1%	21,048 $653,000
Q3 2021 Nov 12, 2021	BUY	$12.98 - $25.03 $303,887 - $586,002	23,412 New	23,412 $568,000

198

84.9M

776K

912K

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $1.3B
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

Get notified when there are updates to the investment portfolio of Dana Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Dana Investment Advisors, Inc. with notifications on news.